|
Sepracor, Inc. Type Public (NASDAQ: SEPR) Founded 1984 Headquarters Marlborough, Massachusetts Key people Timothy J. Barberich, Chairman; Industry Pharmaceuticals Products Lunesta, Xopenex, Brovana Employees 1325 (2009)[1] Website http://www.sepracor.com Sepracor, Inc. (NASDAQ: SEPR) is a pharmaceutical company founded in 1984 by Tim Barberich (President, CEO). It was originally located in Princeton, New Jersey and then re-located in Marlborough, Massachusetts.[2] The company's initial focus was on the development of single isomers and active metabolites. This highly innovative concept allowed Mr. Barberich and Doug Reedich, PhD, JD (Chief Patent Council) to generate an impressive patent estate that served the company well for many, many years. Therapeutically, Sepracor's products were focused on the treatment of central nervous system and respiratory disorders, under the direction of Gunnar Aberg, PhD (VP of Research and Development) and John McCullough, PhD (Director of Research). The primary source of its revenue is the approximately $600 million annually from its Xopenex franchise of drugs, launched under the marketing leadership of John Simon and Medical Communications of Dean Handley, PhD. It is available as a multi-dose inhaler (MDI) or nebulized (UDV) form. However, the blockbuster insomnia drug Lunesta, which was discovered by Tom Jerussi, PhD, approved by the FDA in December 2004 and launched in April 2005 under the marketing leadership of Tim Healy, is on pace to exceed $1 billion in annual sales. In addition, on February 13, 2006, Sepracor filed a new drug application (NDA) for Brovana, patented by Gunnar Aberg and John Morley, PhD (also launched under John Simon) to treat Chronic Obstructive Pulmonary Disease (COPD). All of the launch drugs were manufactured under the leadership of Walter Piskorski. However, under the recent leadership of Adrian Adams, the company has been plagued by drastically falling stock prices, lower revenues than forecasted, company-wide dissatisfaction with leadership and a January 29, 2009 announcement of 530 lay-offs. This layoff and financial hardship of the company employees must be viewed with respect the the fact that Mr. Adams, considered a highly unpopular and arrogant CEO, was the seventh highest paid CEO in Massachusetts in 2007, with a gross compensation $16.4 million. [3] Contents [hide] 1 Beneficiaries, Partners, and Subsidiaries 1.1 Acadia Pharmaceuticals 1.2 Schering-Plough 1.3 Sanofi-Aventis 1.4 Sepracor Canada Ltd. 1.5 GlaxoSmithKline 1.6 Nycomed 1.7 BIA 2-093 2 See also 3 References 4 External links // Beneficiaries, Partners, and Subsidiaries Acadia Pharmaceuticals On January 11, 2005, Sepracor partnered to advance a joint muscarinic-1 receptor agonist program for neuropathic pain. Schering-Plough In December 1997 Schering-Plough obtained exclusive worldwide rights to Sepracor's patents relating to desloratadine, discovered and patented by Dean Handley, PhD (Top 100
|